Paul P. Tak

Academic Medical Center — Netherlands

Medicine · Health Sciences

119h-index60.8kcitations623works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(302), Systemic Lupus Erythematosus Research(155), Monoclonal and Polyclonal Antibodies Research(99), Autoimmune and Inflammatory Disorders Research(83), Spondyloarthritis Studies and Treatments(64)

Publications615 total

513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
Regular and Young Investigator Award Abstracts·2025Open Access
893 Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering
Regular and Young Investigator Award Abstracts·2025Open Access
MA10.02 CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients With Stage III/IV NSCLC With Inadequate Response to ICI
Journal of Thoracic Oncology·2025
The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients
Frontiers in Immunology·2025Open Access
Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes
Arthritis Research & Therapy·2025· 2 citedOpen Access
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer.
Journal of Clinical Oncology·2025· 1 cited
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma
Neuro-Oncology·2025· 4 citedOpen Access
995 Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma
Regular and Young Investigator Award Abstracts·2024Open Access
The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study
RMD Open·2024· 5 citedOpen Access
MA16.08 Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC
Journal of Thoracic Oncology·2024
Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.
Journal of Clinical Oncology·2024· 8 cited
Abstract LB263: A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors
Cancer Research·2024
1348 Development of enLIGHTEN™ Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
1096 A novel viral immunotherapeutic targeting the CD47/SIRPα axis demonstrates potent anti-tumor effects
Regular and Young Investigator Award Abstracts·2023Open Access
653 Neoadjuvant CAN-2409+Prodrug plus chemoradiation for borderline resectable or locally advanced non-metastatic pancreatic adenocarcinoma (PDAC)
Regular and Young Investigator Award Abstracts·2023· 2 citedOpen Access
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Nature·2023· 217 citedOpen Access
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Journal of Clinical Oncology·2023· 2 cited
Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
Frontiers in Medicine·2023· 5 citedOpen Access
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
JCI Insight·2022· 108 citedOpen Access
1134 Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using kaede photoconvertible transgenic mice
Regular and Young Investigator Award Abstracts·2022Open Access
page 1 of 31Next →

Frequent Co-authors

Paul Emery(10), T. Huizinga(9), Niek de Vries(8), Daniëlle M. Gerlag(8), Lars Klareskog(7), Gertjan Wolbink(6), Gerd R Burmester(5), Karen H. Costenbader(5), Jane Worthington(5), Tom Smeets(5), Ferdinand C. Breedveld(5), Dominique Baeten(5), Iain B. McInnes(5), Maxime Dougados(4), Johanna M. W. Hazes(4), Philip J. Mease(4), Jing Cui(4), René E. M. Toes(4), Stephen Eyre(4), Lindsey A. Criswell(4)